Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2013, Article ID 135798, 8 pages
http://dx.doi.org/10.1155/2013/135798
Clinical Study

Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

1Department of Ophthalmology, Charles University, Medical Faculty and Faculty Hospital, Hradec Králové, Czech Republic
2Second Department of Internal Medicine, Haematology, Charles University, Medical Faculty and Faculty Hospital, Hradec Králové, Czech Republic
3Department of Gerontology and Metabolic Care, Charles University, Medical Faculty and Faculty Hospital, Hradec Králové, Czech Republic
4Department of Ophthalmology, University Hospital, Ostrava, Czech Republic

Received 8 August 2013; Accepted 14 November 2013

Academic Editor: Gabriele Thumann

Copyright © 2013 Jan Studnička et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36–1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41–1.0) 95% CI ( ). In the control group, the baseline BCVA was 0.71 (0.15–1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32–0.87) 95% CI ( ). Baseline DPED was 6.78 ± 3.79 mm2; after 3.5 years, it decreased to 4.13 ± 3.84 mm2 ( ). In the control group, the baseline DPED was 4.09 ± 3.48 mm2; after 3.5 years, it increased to 6.69 ± 4.2 mm2 ( ). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment ( ) and a stable amplitude of photopic responses of treated patients. Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA.